Rheos Medicines Revenue and Competitors

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • Rheos Medicines's estimated annual revenue is currently $2.9M per year.(i)
  • Rheos Medicines received $60.0M in venture funding in March 2018.
  • Rheos Medicines's estimated revenue per employee is $77,500
  • Rheos Medicines's total funding is $60M.

Employee Data

  • Rheos Medicines has 37 Employees.(i)
  • Rheos Medicines grew their employee count by -39% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Rheos Medicines is a biopharmaceutical company developing novel medicines that modulate metabolic pathways in immune cells to treat disease. Our approach targets the underlying cellular metabolism of immune cells in order to redirect the fate and function of specific cell types to treat immune-mediated disease. By simultaneously identifying new drug targets and characterizing biomarkers of disease, we are, for the first time, bringing precision to treatment of immune-mediated diseases. We have brought together leading scientists whose discoveries opened the field of immunometabolism, clinicians with a deep understanding of the heterogeneity of immune-mediated disease, and an experienced biotech leadership team. Rheos was founded by Third Rock Ventures and is located in Cambridge, MA. For more information, please visit www.rheosrx.com.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Rheos Medicines News

2022-04-17 - Rheos Medicines Announces New Scientific Advisory Board ...

“Rheos's approach to precision medicine for autoimmune and inflammatory diseases represents a promising path to treating these complex and...

2022-04-17 - Rheos Medicines Appoints Katerina Leftheris, Ph.D., as SVP ...

Rheos Medicines Appoints Katerina Leftheris, Ph.D., as SVP of Drug Discovery and Nabil Uddin, Pharm.D., as VP of Strategy and Business...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Rheos Medicines Funding

DateAmountRoundLead InvestorsReference
2018-03-23$60.0MAThird Rock Ventures, LLCArticle